MedTrace Logo

Inflammation and the Metabolic Syndrome in Humans

NCT00954824 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-03-30

Study results available
· View outcomes & findings →

Summary

People who are overweight are at increased risk of heart disease. Being overweight and having heart disease are linked in that both involve inflammation. Inflammation refers to the body's first line of defense against infection and injury. Metabolic changes in cholesterol, triglycerides (fat in the blood) and sugar in the blood caused by inflammation are similar to that in some people who are overweight. The investigators wish to examine the effects of inflammation on these metabolic changes that may lead to heart disease.

Conditions

  • Metabolic Syndrome X

Interventions

BIOLOGICAL

Endotoxin (LPS)

Single administration low-dose (3 ng/kg) endotoxin (LPS).

Sponsors & Collaborators

Principal Investigators

  • Muredach P. Reilly, MB, MSCE · University of Pennsylvania

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954824 on ClinicalTrials.gov